argumentA line of reasoning from premises to a conclusion. Like a claim, it belongs to no one who makes it.constitution →

Pleiotropy of lipid variants

againstThis argument, if it holds, weighs against the claim.constitution →Genetic instruments for LDL cholesterol affect cardiovascular risk only through LDL and not through confounding pleiotropy

The argument

Given that linked claim, some instruments may influence cardiovascular risk through those other lipid pathways rather than through LDL alone, which would violate the exclusion restriction the claim asserts.

Does it work?

Not yet evaluated.

Premises

VerifiedThe evidence, examined directly, establishes the claim.constitution →Genetic variants that lower LDL cholesterol frequently also affect other lipid traits such as triglycerides and HDL

Where it is made

Passages where sources make, criticize or mention this argument. They record where it appears, not how strong it is, and none has precedence over another.

No source is recorded as making it.

Earlier ratings

Jul 19, 2026
The inference is valid in principle, and its premise is on firm footing: because LDL-lowering variants frequently affect other lipid traits is verified, some instruments could in principle transmit their effect through non-LDL pathways, violating the exclusion restriction. The caveat is that this establishes only a possibility of bias, not that any non-LDL pathway carries a material share of the genetic effect. That possibility is blunted by the multivariable analyses that condition on HDL and triglycerides yet leave LDL's estimate intact, by concordance of estimates across distinct genes, by the absence of directional pleiotropy in sensitivity analyses, and by agreement with randomized trials once exposure duration is accounted for, so the argument weakens the strict statement to an idealization without overturning the operative claim.
Jul 19, 2026
The inference is valid in principle, and its premise is on firm footing: because LDL-lowering variants frequently affect other lipid traits is verified, some instruments could in principle transmit their effect through non-LDL pathways, violating the exclusion restriction. The caveat is that this establishes only a possibility of bias, not that any non-LDL pathway carries a material share of the genetic effect on cardiovascular risk. That possibility is now more firmly blunted by the multivariable analyses that condition on HDL and triglycerides yet leave LDL's estimate intact, by concordance of estimates across distinct genes, and by trial agreement once exposure duration is accounted for, so the argument weakens the strict statement to an idealization without overturning the operative claim.
Jul 19, 2026
The inference is valid in principle, and its premise is on firm footing: because LDL-lowering variants frequently affect other lipid traits is verified, some instruments could in principle transmit their effect through non-LDL pathways, violating the exclusion restriction. The caveat is that this establishes only a possibility of bias, not that any non-LDL pathway carries a material share of the genetic effect on cardiovascular risk. That possibility is substantially blunted by the concordance of per-unit estimates across distinct genes, by multivariable analyses that condition on HDL and triglycerides yet leave LDL's causal estimate intact, and by the trial agreement that holds once exposure duration is accounted for, so the argument weakens the strict statement to an idealization without overturning the operative claim.
Jul 19, 2026
The inference is valid in principle, and its premise is now on firmer footing: because LDL-lowering variants frequently affect other lipid traits is verified, some instruments could in principle transmit their effect through non-LDL pathways, violating the exclusion restriction. The caveat is that this establishes only a possibility of bias, not that any non-LDL pathway carries a material share of the genetic effect on cardiovascular risk. That possibility is substantially blunted by the concordance of per-unit estimates across distinct genes and by multivariable analyses that condition on HDL and triglycerides yet leave LDL's causal estimate intact, so the argument weakens the strict statement to an idealization without overturning the operative claim.
Jul 19, 2026
The inference is valid in principle: because LDL-lowering variants frequently affect other lipid traits, some instruments could in principle transmit their effect through non-LDL pathways, violating the exclusion restriction. The caveat is that this establishes only a possibility of bias, not that any non-LDL pathway carries a material share of the genetic effect on cardiovascular risk. That possibility is substantially blunted by the concordance of per-unit estimates across distinct genes and by drug-target and multivariable-MR corrections, which leave the LDL causal estimate intact, so the argument weakens the strict statement to an idealization without overturning the operative claim.
Jul 19, 2026
The inference is valid as a threat to the strict claim: because LDL-lowering variants frequently affect other lipid traits, individual instruments can in principle influence cardiovascular risk through non-LDL pathways, so the single-pathway statement is an idealization rather than literally true. Its force is bounded, however: the argument establishes that pleiotropy exists, not that it materially biases the LDL causal estimate, and the corrective methods (cis/drug-target instruments, multivariable and outlier-robust MR) together with the concordance and trial-agreement evidence leave that estimate intact. It therefore explains why the claim is supported rather than verified, without contradicting it.